Key result
Mavacamten modulates the myosin cycle by decreasing phosphate release and reducing strongly bound actin-binding heads.
Population
β-cardiac myosin-S1 (preclinical kinetic analysis model)
Design
Preclinical
Authors
Loading...
Refines myosin inhibition models in HCM animals; leaves open human translation and therapeutic optimization.
Mavacamten reduces cardiac contractility in hypertrophic cardiomyopathy by acting on multiple stages of the myosin chemomechanical cycle, primarily by decreasing phosphate release.
Kawas et al. (2017) studied Hypertrophic cardiomyopathy. Mavacamten was evaluated on Myosin chemomechanical cycle kinetics. Mavacamten modulates multiple stages of the myosin chemomechanical cycle by decreasing phosphate release and reducing the number of actin-binding heads transitioning to the strongly bound state.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: